[go: up one dir, main page]

ECSP14030098A - Formas cristalinas de un modulador del receptor androgénico - Google Patents

Formas cristalinas de un modulador del receptor androgénico

Info

Publication number
ECSP14030098A
ECSP14030098A ECIEPI201430098A ECPI201430098A ECSP14030098A EC SP14030098 A ECSP14030098 A EC SP14030098A EC IEPI201430098 A ECIEPI201430098 A EC IEPI201430098A EC PI201430098 A ECPI201430098 A EC PI201430098A EC SP14030098 A ECSP14030098 A EC SP14030098A
Authority
EC
Ecuador
Prior art keywords
androgen receptor
receptor modulator
crystalline forms
modulator
trifluoromethylpyridin
Prior art date
Application number
ECIEPI201430098A
Other languages
English (en)
Inventor
Anna Dilhas
Ouathek Ouerfelli
Mark Herbert
Nicholas Smith
Original Assignee
Aragon Pharmaceuticals Inc
Sloan Kettering Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49712550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14030098(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aragon Pharmaceuticals Inc, Sloan Kettering Inst Cancer Res filed Critical Aragon Pharmaceuticals Inc
Publication of ECSP14030098A publication Critical patent/ECSP14030098A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente descripción se describe formas amorfas y cristalinas del modulador del receptor androgénico 4-[7-(6-ciano-5-trifluorometilpiridin-3-il)-8-oxo-6-tioxo-5,7-diazaspiro[3.4]oct-5-il]-2-fluoro-N-metilbenzamida. Además, se describen composiciones farmacéuticas adecuadas para administrar a un mamífero que incluyen el modulador del receptor androgénico y métodos para usar el modulador del receptor androgénico, solo o en conjunto con otros compuestos, para tratar enfermedades o afecciones asociadas con la actividad del receptor androgénico.
ECIEPI201430098A 2012-06-07 2014-12-05 Formas cristalinas de un modulador del receptor androgénico ECSP14030098A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261656888P 2012-06-07 2012-06-07

Publications (1)

Publication Number Publication Date
ECSP14030098A true ECSP14030098A (es) 2016-01-29

Family

ID=49712550

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201430098A ECSP14030098A (es) 2012-06-07 2014-12-05 Formas cristalinas de un modulador del receptor androgénico

Country Status (45)

Country Link
US (9) US9481663B2 (es)
EP (4) EP3533792B1 (es)
JP (3) JP6182209B2 (es)
KR (2) KR102195916B1 (es)
CN (3) CN104619692A (es)
AU (3) AU2013271751B2 (es)
BR (1) BR112014030678A2 (es)
CA (4) CA3114726A1 (es)
CL (1) CL2014003331A1 (es)
CO (1) CO7240407A2 (es)
CR (2) CR20190331A (es)
CY (4) CY1120393T1 (es)
DK (3) DK3533792T3 (es)
EA (3) EA201992010A1 (es)
EC (1) ECSP14030098A (es)
ES (3) ES2670683T3 (es)
FR (1) FR21C1050I2 (es)
GT (1) GT201400283A (es)
HK (2) HK1210175A1 (es)
HR (3) HRP20180902T1 (es)
HU (4) HUE054595T2 (es)
IL (5) IL267608B1 (es)
IN (1) IN2014DN10084A (es)
LT (4) LT2858985T (es)
LU (1) LUC00236I2 (es)
ME (2) ME03081B (es)
MX (1) MX356754B (es)
MY (1) MY187500A (es)
NI (1) NI201400142A (es)
NL (1) NL301144I2 (es)
NO (1) NO2021046I1 (es)
NZ (2) NZ717683A (es)
PE (3) PE20200725A1 (es)
PH (2) PH12014502714B1 (es)
PL (3) PL3533792T3 (es)
PT (3) PT3348553T (es)
RS (3) RS61988B1 (es)
SG (3) SG10201610249TA (es)
SI (3) SI2858985T1 (es)
SM (3) SMT202100355T1 (es)
TR (1) TR201808939T4 (es)
TW (1) TWI532732B (es)
UA (2) UA123142C2 (es)
WO (1) WO2013184681A1 (es)
ZA (1) ZA201500076B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461343B2 (en) 2007-03-27 2013-06-11 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
JP2015505856A (ja) 2011-12-16 2015-02-26 オレマ ファーマシューティカルズ インク． 新規のベンゾピラン化合物、その組成物および使用
WO2013184681A1 (en) 2012-06-07 2013-12-12 Aragon Pharmaceuticals, Inc. Crystalline forms of an androgen receptor modulator
EP3971167A1 (en) 2012-09-11 2022-03-23 Medivation Prostate Therapeutics LLC Formulations of enzalutamide
MY180834A (en) 2012-09-26 2020-12-10 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
JP2017525727A (ja) * 2014-08-26 2017-09-07 アスター バイオテック リミテッド ライアビリティ カンパニー プロテインキナーゼ阻害剤
AU2015358497B2 (en) 2014-12-05 2021-04-29 Aragon Pharmaceuticals, Inc. Anticancer compositions
CA2969656A1 (en) * 2014-12-05 2016-06-09 Aragon Pharmaceuticals, Inc. Solid formulations of arn-509 and hydroxypropyl methylcellulose acetate succinate
HUE051888T2 (hu) 2014-12-05 2021-03-29 Aragon Pharmaceuticals Inc Rákellenes készítmények
WO2016100905A1 (en) 2014-12-19 2016-06-23 Lutron Electronics Co., Inc. Multi-channel lighting fixture having multiple light-emitting diode drivers
CR20180600A (es) 2016-06-03 2019-07-11 Aragon Pharmaceuticals Inc Composiciones anticancerigenas
WO2018112001A1 (en) 2016-12-13 2018-06-21 Watson Laboratories Inc. Solid state forms of apalutamide
BR112020007439A2 (pt) 2017-10-16 2020-10-27 Aragon Pharmaceuticals, Inc. antiandrogênios para o tratamento de câncer de próstata resistente à castração não metastática
WO2019135254A1 (en) * 2018-01-02 2019-07-11 Mylan Laboratories Limited Apalutamide polymorphs and their preparation thereof
US20200270226A1 (en) * 2018-06-20 2020-08-27 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystalline forms of arn-509, preparation method and use thereof
WO2020049598A2 (en) 2018-09-08 2020-03-12 Cipla Limited Apalutamide polymorphs
IT201900003839A1 (it) 2019-03-15 2020-09-15 Olon Spa Sintesi di apalutamide amorfa stabile
WO2020234817A1 (en) * 2019-05-21 2020-11-26 Laurus Labs Limited Polymorphic forms of apalutamide and its preparation thereof
IT201900010593A1 (it) * 2019-07-01 2021-01-01 Dipharma Francis Srl Forma cristallina di un inibitore di recettori degli androgeni
EP4017848A1 (en) * 2019-08-22 2022-06-29 Dr. Reddy's Laboratories Ltd. Process for the preparation of apalutamide
IT201900015974A1 (it) 2019-09-10 2021-03-10 Olon Spa Apalutamide cristallina stabile in forma pura e processo per la sua preparazione
CN110590740A (zh) * 2019-09-20 2019-12-20 武汉大学 一种阿帕鲁胺化合物及其药物制剂
EP4541786A2 (en) 2020-09-04 2025-04-23 Synthon B.V. Improved process for preparation of apalutamide
CN112679468A (zh) * 2021-01-05 2021-04-20 四川科伦药物研究院有限公司 阿帕他胺的晶体形式、制备方法和用途
WO2023143090A1 (zh) * 2022-01-25 2023-08-03 成都苑东生物制药股份有限公司 一种阿帕他胺溶剂化物新晶型及其制备方法
CN115536634B (zh) * 2022-10-17 2024-06-11 上海博悦生物科技有限公司 一种阿帕他胺的合成方法
CN116332907A (zh) * 2023-03-16 2023-06-27 奥锐特药业股份有限公司 一种无定形阿帕他胺的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
CN101032483B (zh) * 2006-03-09 2011-05-04 陈德桂 调节雄激素受体活性的乙内酰脲衍生物及其应用
LT3412290T (lt) 2006-03-27 2021-04-26 The Regents Of The University Of California Androgeno receptorių moduliatorius, skirtas prostatos vėžio bei su androgeno receptoriais susijusių ligų gydymui
SG170809A1 (en) 2006-03-29 2011-05-30 Univ California Diarylthiohydantoin compounds
US8461343B2 (en) 2007-03-27 2013-06-11 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
EP2536708A4 (en) * 2010-02-16 2013-05-29 Aragon Pharmaceuticals Inc ANDROGEN RECEPTOR MODULATORS AND USES THEREOF
WO2013184681A1 (en) * 2012-06-07 2013-12-12 Aragon Pharmaceuticals, Inc. Crystalline forms of an androgen receptor modulator
US20200270226A1 (en) 2018-06-20 2020-08-27 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystalline forms of arn-509, preparation method and use thereof

Also Published As

Publication number Publication date
ME03815B (me) 2021-04-20
US20200354335A1 (en) 2020-11-12
MX356754B (es) 2018-06-11
DK3533792T3 (da) 2021-06-28
EP3348553A1 (en) 2018-07-18
CN113135892A (zh) 2021-07-20
SG11201408140QA (en) 2015-01-29
IL259738A (en) 2018-07-31
ES2875932T3 (es) 2021-11-11
PH12016501470A1 (en) 2017-07-10
EA201492272A1 (ru) 2015-05-29
FR21C1050I2 (fr) 2024-05-24
JP2015518890A (ja) 2015-07-06
HK1210175A1 (en) 2016-04-15
IL320522A (en) 2025-06-01
ES2670683T3 (es) 2018-05-31
HUE050357T2 (hu) 2020-11-30
AU2013271751B2 (en) 2017-02-23
HRP20180902T1 (hr) 2018-08-24
PT3348553T (pt) 2020-09-28
LT3348553T (lt) 2020-09-25
EP3922629A1 (en) 2021-12-15
TW201402561A (zh) 2014-01-16
EP3348553B1 (en) 2020-07-08
ES2809738T3 (es) 2021-03-05
PL3348553T3 (pl) 2021-02-08
IL275413A (en) 2020-07-30
US10766875B2 (en) 2020-09-08
GT201400283A (es) 2017-07-03
WO2013184681A1 (en) 2013-12-12
SMT202100355T1 (it) 2021-07-12
JP2018141009A (ja) 2018-09-13
HK1226066A1 (zh) 2017-09-22
US10526310B2 (en) 2020-01-07
LUC00236I2 (es) 2025-02-03
RS60617B1 (sr) 2020-09-30
LT3533792T (lt) 2021-07-26
US20200115361A1 (en) 2020-04-16
NZ717683A (en) 2018-04-27
CA2875767C (en) 2018-08-14
BR112014030678A2 (pt) 2017-06-27
JP6345821B2 (ja) 2018-06-20
NL301144I2 (nl) 2025-03-20
NO2021046I1 (no) 2021-11-02
HUE038082T2 (hu) 2018-09-28
EA201992010A1 (ru) 2020-01-24
CN105693692A (zh) 2016-06-22
PH12016501470B1 (en) 2021-12-10
NI201400142A (es) 2016-12-02
US10934271B2 (en) 2021-03-02
CY1124831T1 (el) 2022-03-24
KR102195916B1 (ko) 2020-12-30
US20190241539A1 (en) 2019-08-08
JP2017178923A (ja) 2017-10-05
DK2858985T3 (en) 2018-05-28
HUE054595T2 (hu) 2021-09-28
PE20150631A1 (es) 2015-05-11
KR20190132543A (ko) 2019-11-27
US20190330182A1 (en) 2019-10-31
ZA201500076B (en) 2016-10-26
DK3348553T3 (da) 2020-07-27
PH12014502714A1 (en) 2015-02-02
EP2858985A4 (en) 2016-05-25
RS57370B1 (sr) 2018-08-31
PE20200725A1 (es) 2020-07-21
PH12014502714B1 (en) 2015-02-02
US10308630B2 (en) 2019-06-04
AU2017279807A1 (en) 2018-01-25
KR102062024B1 (ko) 2020-01-03
SMT202000496T1 (it) 2020-11-10
NZ702203A (en) 2016-09-30
US9994545B2 (en) 2018-06-12
US20210163441A1 (en) 2021-06-03
CA3055660A1 (en) 2013-12-12
CY1120393T1 (el) 2019-07-10
HRP20201387T1 (hr) 2020-11-27
EA201791592A1 (ru) 2018-01-31
IL236055A0 (en) 2015-02-01
MY187500A (en) 2021-09-24
SMT201800311T1 (it) 2018-07-17
CL2014003331A1 (es) 2016-03-04
FR21C1050I1 (fr) 2021-12-10
PT2858985T (pt) 2018-07-10
KR20150021993A (ko) 2015-03-03
CA2875767A1 (en) 2013-12-12
AU2013271751A1 (en) 2014-12-18
AU2017200298A1 (en) 2017-02-02
HUS2100047I1 (hu) 2021-11-29
SG10201610249TA (en) 2017-02-27
LTPA2021525I1 (es) 2021-11-25
CO7240407A2 (es) 2015-04-17
SI3533792T1 (sl) 2021-11-30
CR20190331A (es) 2019-11-12
TWI532732B (zh) 2016-05-11
CN104619692A (zh) 2015-05-13
EP3533792A1 (en) 2019-09-04
CR20140549A (es) 2015-04-06
US10556882B2 (en) 2020-02-11
PL2858985T3 (pl) 2018-09-28
US12018008B2 (en) 2024-06-25
IN2014DN10084A (es) 2015-08-21
PL3533792T3 (pl) 2021-11-29
IL267608A (en) 2019-08-29
CA3008345A1 (en) 2013-12-12
CY2021032I2 (el) 2022-03-24
IL259738B (en) 2021-06-30
LT2858985T (lt) 2018-09-25
JP6182209B2 (ja) 2017-08-16
EP2858985A1 (en) 2015-04-15
PT3533792T (pt) 2021-06-07
RS61988B1 (sr) 2021-07-30
AU2017279807B2 (en) 2018-11-08
IL267608B1 (en) 2025-06-01
US20180258067A1 (en) 2018-09-13
CA3008345C (en) 2019-10-22
CA3114726A1 (en) 2013-12-12
EP3533792B1 (en) 2021-05-05
UA123142C2 (uk) 2021-02-24
US20170001977A1 (en) 2017-01-05
US20250092011A1 (en) 2025-03-20
CY1123427T1 (el) 2021-12-31
EA028791B1 (ru) 2017-12-29
PE20200795A1 (es) 2020-08-10
SI2858985T1 (sl) 2018-12-31
US9481663B2 (en) 2016-11-01
EA033956B1 (ru) 2019-12-13
UA115665C2 (uk) 2017-12-11
HRP20210909T1 (hr) 2021-09-03
AU2017200298B2 (en) 2017-09-28
TR201808939T4 (tr) 2018-07-23
US20150133481A1 (en) 2015-05-14
ME03081B (me) 2019-01-20
MX2014015005A (es) 2015-09-04
SI3348553T1 (sl) 2020-11-30
EP2858985B1 (en) 2018-04-18
CY2021032I1 (es) 2022-03-24
SG10201610248SA (en) 2017-02-27

Similar Documents

Publication Publication Date Title
ECSP14030098A (es) Formas cristalinas de un modulador del receptor androgénico
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
NZ702663A (en) Nuclear transport modulators and uses thereof
MX2015016983A (es) Moduladores del transporte nuclear y usos de los mismos.
GT201300215A (es) Inhibidores de glucosilceramida sintasa
CR20150265A (es) Formas de dosificación de ruxolitinib de liberación sostenida
UY32809A (es) Compuestos y composiciones como inhibidores de cinasa s y k
UY35916A (es) Compuestos tricíclicos como agentes antineoplásicos inhibidores del bromodominio
CL2013002650A1 (es) Compuestos derivados triciclicos con actividad sobre los receptores hormonales nucleares; composicion farmaceutica que los comprende; proceso de reparacion de compuestos intermediarios; y uso en el tratamiento del sida, insuficiencia adrenal aguda, enfermedad de addison, rinitis alergica, enfermedad de alzheimer, entre otros.
GT201500035A (es) Composición farmacéutica oral en forma de microesferas y proceso de elaboración
CL2015001610A1 (es) Compuestos derivados de pirimido-[4,5-b]-quinolina-4,5(3h,10h)-dionas para utilizarse como un medicamento para el tratamiento de una enfermedad causada por una mutacion sin sentido; composicion y combinacion farmaceutica que los comprende.
ECSP16012582A (es) Compuestos heterocíclicos y métodos de uso
DOP2014000114A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
CR20160290A (es) Inhibidores tetracíclicos de autotaxina
GT201300304A (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
CL2009000876A1 (es) Forma cristalina maleato de orvepitant anhidro; composicion farmaceutica; y su uso para tratar trastornos del sistema nervioso central, tales como depresion, ansiedad, trastornos de estres postraumatico, emesis y/o trastornos del sueno.
PE20151669A1 (es) Compuestos de azetidiniloxifenilpirrolidina
CL2015001502A1 (es) Composición farmacéutica que comprende desloratadina y prendnisolona y uso de la misma.
MX2015012043A (es) Agonistas muscarinicos.
CL2011002626A1 (es) Compuestos derivados de piperazina, como antagonistas del receptor p2y12; composicion farmaceutica que los contienen; y su uso en el tratamiento de trastornos vasculares oclusivos.
UY32679A (es) Antagonistas policíclicos de receptores de ácido lisofosfatidico